EMA reopens its animal-testing alternatives channel after a decade of near-zero uptake

The European Medicines Agency launched a voluntary data submission pilot on 1 September to let developers share data generated with New Approach Methodologies — organoids, microphysiological systems, computational models and combinations of them — with regulators outside the context of a marketing authorisation application [s1].

The most useful sentence in the accompanying information document is not about the new pilot. It is about the old mechanism: the safe harbour procedure introduced by EMA's 2012 guideline on regulatory acceptance of 3Rs testing approaches "has seen little to no uptake since the publication of the guideline" [s2].

What the safe harbour was, and why it failed

The 2012 guideline created a route for data generated with novel 3Rs approaches — replace, reduce, refine — to be submitted alongside data from established methods in support of a marketing authorisation application [s2]. The intent was to let regulators define appropriate contexts of use, assess methodological readiness and limitations, and build experience and confidence in data from novel methods [s2].

Fourteen years later, EMA's own assessment is that practical experience with New Approach Methodologies inside the EU regulatory system remains limited, and that key questions about feasibility, incentives, data handling and regulatory added value remain unexplored [s2].

The document is specific about why. Industry has substantial in-house expertise and routinely applies these methods in early-stage drug discovery and development, but sharing with regulators is typically case-by-case, mainly to support weight-of-evidence approaches in toxicological assessments [s2]. Because these methods are not part of regulatory-required testing, the resulting data are often not included in clinical trial applications or marketing authorisation dossiers at all [s2]. When data are shared, they are frequently provided for information only, without enough context or supporting background to enable systematic regulatory learning [s2].

That is a clear-eyed diagnosis. The safe harbour attached the submission to a marketing application, which meant a company had to weigh the value of educating a regulator against the risk of complicating its own dossier. Detaching the two is precisely what the new pilot does.

What the pilot is

The pilot is described as a voluntary, non-binding and non-decisional mechanism that does not replace or interfere with existing regulatory procedures [s2]. Participants receive individual, non-binding and non-decisional feedback from an operational expert group of non-clinical experts drawn from across the European medicines regulatory network [s1].

Eligibility is broad: companies, contract research organisations, method developers, non-governmental organisations, academic laboratories, consortia and others [s2]. The process runs in stages — expression of interest via an application form, EMA internal validation and prioritisation, an invitation to selected applicants to submit a full briefing package, and submission through EMA's secure file transfer system, with data stored in a secure environment and used exclusively for the pilot [s2].

Scope is bounded. Only data falling within predefined contexts of use and regulatory applicability areas will be assessed and analysed [s2]. Assessment of briefing packages is expected to follow the scientific advice timeline, though EMA notes this may vary with the number, prioritisation and complexity of submissions and expert group availability [s2].

The timeline

The pilot was presented at a kick-off meeting with industry stakeholders on 11 December 2025, at which it became clear that more industry input was needed to prioritise which regulatory applicability areas the pilot should target [s2]. EMA circulated a stakeholder survey in January 2026 to gather that input [s2]. The pilot launches in the third quarter of 2026, the call for data remains open until the third quarter of 2027, and assessment and analysis continue through 2027 [s2]. Submissions are expected until the third quarter of 2027, after which EMA will publish a lessons-learned report [s1].

What it is not

This is the part most likely to be lost in the retelling. The pilot does not qualify any method, accept any method for regulatory use, or reduce any animal testing requirement. Feedback is explicitly non-binding and non-decisional [s2]. What a participant gets is an assessment of regulatory relevance, strengths and limitations within a defined context of use, and guidance on possible follow-up through existing routes — Innovation Task Force briefings, scientific advice or qualification advice [s2].

EMA's own framing is that the pilot is an exploratory step to test the feasibility, scope and added value of voluntary submissions, and to generate evidence that could inform a more structured framework later [s2]. Note also that the definition of New Approach Methodologies used in the document is described as provisional, pending finalisation of a glossary in an ongoing revision of the 3Rs guideline [s2].

Why it matters anyway

The bottleneck in replacing animal testing has not primarily been whether human-derived models exist. It has been whether a regulator has enough accumulated experience with a given model, in a given context of use, to accept it in place of a study it already knows how to read. That experience can only come from seeing data. A channel that lets a regulator see data without a company staking a dossier on it is a modest thing that addresses the actual constraint.

What to watch

Three checkable things. How many expressions of interest EMA receives, given that the predecessor mechanism received almost none [s2]. Which regulatory applicability areas were prioritised after the January 2026 stakeholder survey [s2]. And the lessons-learned report at the end of the pilot, which is where the difference between a channel that works and a channel that is merely open will be visible [s1].

Sources

• Voluntary data submission pilot to advance innovative alternatives to animal testing, European Medicines Agency, 1 September 2026
• Information about the Voluntary Data Submission pilot: data sharing on New Approach Methodologies under voluntary submission (EMA/149393/2026), European Medicines Agency, published 1 September 2026